EUVIMEDEUVIMED entdecken
FallberichtLeserbriefOpen Access · CC BY 4.0

Acquired MTAP Loss Following Entrectinib Resistance in ROS1 ‐Rearranged NSCLC With CD74 Exon 3– ROS1 Exon 34 Fusion

Mizuha Haraguchi Hashiguchi iD, Maika Tanino, Suzuyuki Yoneda, Masato Asaoka, Junko Kagyo, Makoto Katayama, Hideki Terai, Kohei Nakamura, Hiroshi Nishihara, Koichi Fukunaga

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70176 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Mizuha Haraguchi Hashiguchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Medicine, Department of Medicine, Keiyu Hospital, Yokohama, Japan. Hauptthemen laut MEDLINE: Antigens, Differentiation, B-Lymphocyte, Benzamides, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, Differentiation, B-LymphocyteBenzamidesCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmHistocompatibility Antigens Class IIIndazolesLung NeoplasmsOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsHumansExonsGene Rearrangement

Substanzen

Antigens, Differentiation, B-LymphocyteBenzamidesentrectinibHistocompatibility Antigens Class IIIndazolesinvariant chainOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsROS1 protein, human

Autor:innen und Institutionen

  • Division of Pulmonary Medicine, Department of Medicine, Keiyu Hospital, Yokohama, Japan.
  • Department of Neurosurgery, Kawasaki Municipal Hospital, Kawasaki, Japan.
  • Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Tokyo, Japan.
  • Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
  • Center for Cancer Genomics, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Mizuha Haraguchi Hashiguchi

Zitieren

APA

Haraguchi Hashiguchi, M., Tanino, M., Yoneda, S., Asaoka, M., Kagyo, J., Katayama, M., Terai, H., Nakamura, K., Nishihara, H., & Fukunaga, K. (2025). Acquired MTAP Loss Following Entrectinib Resistance in ROS1 ‐Rearranged NSCLC With CD74 Exon 3– ROS1 Exon 34 Fusion. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70176

Vancouver

Haraguchi Hashiguchi M, Tanino M, Yoneda S, Asaoka M, Kagyo J, Katayama M, et al. Acquired MTAP Loss Following Entrectinib Resistance in ROS1 ‐Rearranged NSCLC With CD74 Exon 3– ROS1 Exon 34 Fusion. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70176

BibTeX
@article{HaraguchiHashiguchi2025,
  author = {Haraguchi Hashiguchi, Mizuha and Tanino, Maika and Yoneda, Suzuyuki and Asaoka, Masato and Kagyo, Junko and Katayama, Makoto and Terai, Hideki and Nakamura, Kohei and Nishihara, Hiroshi and Fukunaga, Koichi},
  title = {Acquired MTAP Loss Following Entrectinib Resistance in ROS1 ‐Rearranged NSCLC With CD74 Exon 3– ROS1 Exon 34 Fusion},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70176}
}
Kostenlos starten →